Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax RateWages, Salaries and Other
Others
Ratios

BridgeBio Pharma (BBIO) Net Income towards Common Stockholders (2019 - 2025)

BridgeBio Pharma (BBIO) has disclosed Net Income towards Common Stockholders for 7 consecutive years, with -$192.9 million as the latest value for Q4 2025.

  • Quarterly Net Income towards Common Stockholders rose 27.24% to -$192.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$724.9 million through Dec 2025, down 35.31% year-over-year, with the annual reading at -$724.9 million for FY2025, 35.31% down from the prior year.
  • Net Income towards Common Stockholders hit -$192.9 million in Q4 2025 for BridgeBio Pharma, down from -$182.7 million in the prior quarter.
  • In the past five years, Net Income towards Common Stockholders ranged from a high of -$9.9 million in Q2 2022 to a low of -$265.0 million in Q4 2024.
  • Historically, Net Income towards Common Stockholders has averaged -$147.4 million across 5 years, with a median of -$160.0 million in 2023.
  • Biggest five-year swings in Net Income towards Common Stockholders: soared 89.77% in 2022 and later plummeted 1502.06% in 2023.
  • Year by year, Net Income towards Common Stockholders stood at -$147.2 million in 2021, then increased by 6.51% to -$137.6 million in 2022, then dropped by 22.21% to -$168.1 million in 2023, then tumbled by 57.63% to -$265.0 million in 2024, then increased by 27.24% to -$192.9 million in 2025.
  • Business Quant data shows Net Income towards Common Stockholders for BBIO at -$192.9 million in Q4 2025, -$182.7 million in Q3 2025, and -$181.9 million in Q2 2025.